These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 10688272)

  • 1. Pharmacogenetic methods as a complement to therapeutic monitoring of antidepressants and neuroleptics.
    Dahl ML; Sjöqvist F
    Ther Drug Monit; 2000 Feb; 22(1):114-7. PubMed ID: 10688272
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The convergence of conventional therapeutic drug monitoring and pharmacogenetic testing in personalized medicine: focus on antidepressants.
    Sjöqvist F; Eliasson E
    Clin Pharmacol Ther; 2007 Jun; 81(6):899-902. PubMed ID: 17392719
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic monitoring of antidepressants in the era of pharmacogenetics studies.
    Eap CB; Jaquenoud Sirot E; Baumann P
    Ther Drug Monit; 2004 Apr; 26(2):152-5. PubMed ID: 15228156
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic plasma concentrations of antidepressants and antipsychotics: lessons from PET imaging.
    Gründer G; Hiemke C; Paulzen M; Veselinovic T; Vernaleken I
    Pharmacopsychiatry; 2011 Sep; 44(6):236-48. PubMed ID: 21959785
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The AGNP-TDM Expert Group Consensus Guidelines: focus on therapeutic monitoring of antidepressants.
    Baumann P; Ulrich S; Eckermann G; Gerlach M; Kuss HJ; Laux G; Müller-Oerlinghausen B; Rao ML; Riederer P; Zernig G; Hiemke C;
    Dialogues Clin Neurosci; 2005; 7(3):231-47. PubMed ID: 16156382
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High levels of several antipsychotics and antidepressants due to a pharmacogenetic cause: a case report.
    Mian P; Somers M; Berg MT; Cahn W; Wilting I; Schaik RV
    Pharmacogenomics; 2019 Jun; 20(8):567-570. PubMed ID: 31190622
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The impact of cytochrome P450-2D6 genotype on the use and interpretation of therapeutic drug monitoring in long-stay patients treated with antidepressant and antipsychotic drugs in daily psychiatric practice.
    Mulder H; Herder A; Wilmink FW; Tamminga WJ; Belitser SV; Egberts AC
    Pharmacoepidemiol Drug Saf; 2006 Feb; 15(2):107-14. PubMed ID: 16294366
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Screening for genotypic and phenotypic variations in CYP450 activity in patients with therapeutic problems in a psychiatric setting, a retrospective study.
    Lloret-Linares C; Rollason V; Lorenzini KI; Samer C; Daali Y; Gex-Fabry M; Aubry JM; Desmeules J; Besson M
    Pharmacol Res; 2017 Apr; 118():104-110. PubMed ID: 27378571
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The AmpliChip CYP450 genotyping test: Integrating a new clinical tool.
    de Leon J; Susce MT; Murray-Carmichael E
    Mol Diagn Ther; 2006; 10(3):135-51. PubMed ID: 16771600
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Recommendations for therapeutic monitoring of antidepressants].
    Baumann P; Rougemont M; Corruble E; Hiemke C;
    Rev Med Suisse; 2013 Mar; 9(377):577-86. PubMed ID: 23534245
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacogenetics: the therapeutic drug monitoring of the future?
    Ensom MH; Chang TK; Patel P
    Clin Pharmacokinet; 2001; 40(11):783-802. PubMed ID: 11735602
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytochrome p450 phenotyping/genotyping in patients receiving antipsychotics: useful aid to prescribing?
    Dahl ML
    Clin Pharmacokinet; 2002; 41(7):453-70. PubMed ID: 12083975
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic drug monitoring in Italian psychiatry.
    Conca A; Schmidt E; Pastore M; Hiemke C; Duffy D; Giupponi G
    Pharmacopsychiatry; 2011 Sep; 44(6):259-62. PubMed ID: 21959788
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Pharmacogenetic challenges in the treatment of mental diseases].
    Sukhanov VA; Piruzian LA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2004; 104(8):83-6. PubMed ID: 15554149
    [No Abstract]   [Full Text] [Related]  

  • 15. Pharmacokinetic considerations for current state-of-the-art antidepressants.
    Wyska E
    Expert Opin Drug Metab Toxicol; 2019 Oct; 15(10):831-847. PubMed ID: 31526279
    [No Abstract]   [Full Text] [Related]  

  • 16. Pharmacogenetics of classical and new antipsychotic drugs.
    Otani K; Aoshima T
    Ther Drug Monit; 2000 Feb; 22(1):118-21. PubMed ID: 10688273
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacogenetics: a laboratory tool for optimizing therapeutic efficiency.
    Linder MW; Prough RA; Valdes R
    Clin Chem; 1997 Feb; 43(2):254-66. PubMed ID: 9023127
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Debrisoquin and mephenytoin hydroxylation phenotypes and CYP2D6 genotype in patients treated with neuroleptic and antidepressant agents.
    LLerena A; Herraíz AG; Cobaleda J; Johansson I; Dahl ML
    Clin Pharmacol Ther; 1993 Dec; 54(6):606-11. PubMed ID: 7903915
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Pharmacogenetic aspects of the activity of cytochromes P450 in the metabolism of antipsychotics].
    Fursa OO; Kozlovskiĭ VL
    Zh Nevrol Psikhiatr Im S S Korsakova; 2014; 114(4):111-22. PubMed ID: 25089317
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Treatment-resistant depression and antidepressant plasma level: Proposal of a pharmacogenetic-integrative algorithm from a case report].
    Bourla A; Chaneac E; Ferreri F
    Encephale; 2019 Feb; 45(1):92-94. PubMed ID: 29887302
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.